---
title: The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant
  and refractory high-grade serous ovarian cancer patient-derived xenograft models
date: '2023-11-29'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38028140/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231130170657&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSION: The efficacy observed for eribulin in PRR HGSC PDX was similar
  to that observed for paclitaxel, which transformed ovarian cancer clinical practice.
  Eribulin is therefore worthy of further consideration in clinical trials, particularly
  in ovarian carcinoma with early failure of carboplatin/paclitaxel ...'
disable_comments: true
---
CONCLUSION: The efficacy observed for eribulin in PRR HGSC PDX was similar to that observed for paclitaxel, which transformed ovarian cancer clinical practice. Eribulin is therefore worthy of further consideration in clinical trials, particularly in ovarian carcinoma with early failure of carboplatin/paclitaxel ...